Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Journal (United States) is Scopus-indexed (Q2, CiteScore 4.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Lippincott Williams and Wilkins.
Checked against the index lists dated .
ISSN 1528-9117Verify ISSN ↗1540-336XVerify ISSN ↗
Publisher: Lippincott Williams and Wilkins
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 174 / 428 | 59th | Q2 |
| Cancer Research | 140 / 233 | 40th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2000–present (also 1998, 1996), best quartile Q2, CiteScore 4.7.
Cancer Journal (United States) is Q2 in Oncology (rank 174 of 428) and Q3 in Cancer Research (rank 140 of 233), by CiteScore 2025.
Cancer Journal (United States) is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.7, which places it in quartile Q2 at the 59th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.869, quartile Q2, with an H-index of 110.
Cancer Journal (United States) is published by Lippincott Williams and Wilkins. Its print ISSN is 1528-9117 and its online ISSN is 1540-336X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Journal (United States) has an h-index of 114 and a 2-year mean of 2.17 citations per paper (OpenAlex). Its Scopus CiteScore is 4.7, quartile Q2. On 2-year citations it ranks #176 of 424 Scopus journals in Oncology.
Cancer Journal (United States) published 45 papers in 2025; its busiest recent year was 2020 with 76. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2024–2026), authors are most often from United States (80.6%), United Kingdom (7.7%) and Canada (3.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.